These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
68 related articles for article (PubMed ID: 30860278)
1. Food and drug administration - approved molecular methods for detecting human papillomavirus infection. Sitarz K; Szostek S Ginekol Pol; 2019; 90(2):104-108. PubMed ID: 30860278 [TBL] [Abstract][Full Text] [Related]
2. Comparison of human papillomavirus detection by Aptima HPV and cobas HPV tests in a population of women referred for colposcopy following detection of atypical squamous cells of undetermined significance by Pap cytology. Castle PE; Eaton B; Reid J; Getman D; Dockter J J Clin Microbiol; 2015 Apr; 53(4):1277-81. PubMed ID: 25653409 [TBL] [Abstract][Full Text] [Related]
3. Comparison of the PANArray HPV Genotyping Chip Test with the Cobas 4800 HPV and Hybrid Capture 2 Tests for Detection of HPV in ASCUS Women. Ki EY; Lee YK; Lee A; Park JS Yonsei Med J; 2018 Jul; 59(5):662-668. PubMed ID: 29869464 [TBL] [Abstract][Full Text] [Related]
4. A Comparison of the Roche Cobas HPV Test With the Hybrid Capture 2 Test for the Detection of High-Risk Human Papillomavirus Genotypes. Levi AW; Bernstein JI; Hui P; Duch K; Schofield K; Chhieng DC Arch Pathol Lab Med; 2016 Feb; 140(2):153-7. PubMed ID: 26910220 [TBL] [Abstract][Full Text] [Related]
5. A review of the FDA-approved molecular testing platforms for human papillomavirus. Salazar KL; Duhon DJ; Olsen R; Thrall M J Am Soc Cytopathol; 2019; 8(5):284-292. PubMed ID: 31320315 [TBL] [Abstract][Full Text] [Related]
6. Which high-risk HPV assays fulfil criteria for use in primary cervical cancer screening? Arbyn M; Snijders PJ; Meijer CJ; Berkhof J; Cuschieri K; Kocjan BJ; Poljak M Clin Microbiol Infect; 2015 Sep; 21(9):817-26. PubMed ID: 25936581 [TBL] [Abstract][Full Text] [Related]
8. Laboratory diagnosis of human papillomavirus infection. Ikenberg H Curr Probl Dermatol; 2014; 45():166-74. PubMed ID: 24643185 [TBL] [Abstract][Full Text] [Related]
9. [Investigation of human papillomavirus prevalence in women in Eskişehir, Turkey by Pap smear, hybrid capture 2 test and consensus real-time polymerase chain reaction and typing with pyrosequencing method]. Aslan FG; Us T; Kaşifoğlu N; Özalp SS; Akgün Y; Öge T Mikrobiyol Bul; 2016 Jan; 50(1):73-85. PubMed ID: 27058331 [TBL] [Abstract][Full Text] [Related]
10. Comparison of the analytical and clinical performance of five tests for the detection of human papillomavirus genital infection. Del Pino M; Alonso I; Rodriguez-Trujillo A; Bernal S; Geraets D; Guimerà N; Torne A; Ordi J J Virol Methods; 2017 Oct; 248():238-243. PubMed ID: 28739302 [TBL] [Abstract][Full Text] [Related]
11. High-risk HPV detection and genotyping by APTIMA HPV using cervical samples. Pyne MT; Hamula CL; Tardif K; Law C; Schlaberg R J Virol Methods; 2015 Sep; 221():95-9. PubMed ID: 25956671 [TBL] [Abstract][Full Text] [Related]
12. Comparison of urine and cervical samples for detecting human papillomavirus (HPV) with the Cobas 4800 HPV test. Bernal S; Palomares JC; Artura A; Parra M; Cabezas JL; Robles A; Martín Mazuelos E J Clin Virol; 2014 Dec; 61(4):548-52. PubMed ID: 25453566 [TBL] [Abstract][Full Text] [Related]
13. The reliability of high-risk human papillomavirus detection by Aptima HPV assay in women with ASC-US cytology. Castle PE; Reid J; Dockter J; Getman D J Clin Virol; 2015 Aug; 69():52-5. PubMed ID: 26209379 [TBL] [Abstract][Full Text] [Related]
14. Patient safety and the next generation of HPV DNA tests. Lee SH Am J Clin Pathol; 2011 Mar; 135(3):481; author reply 482-3. PubMed ID: 21350106 [No Abstract] [Full Text] [Related]
15. Comparison of hybrid capture 2 High-Risk HPV results in the low positive range with cobas® HPV Test results from the ATHENA study. Rao A; Sandri MT; Sideri M; Young S; Sharma A; Behrens C J Clin Virol; 2013 Sep; 58(1):161-7. PubMed ID: 23895930 [TBL] [Abstract][Full Text] [Related]
16. Comparison of Cobas® HPV and Anyplex™ II HPV28 assays for detecting and genotyping human papillomavirus. Pasquier C; Sauné K; Raymond S; Boisneau J; Courtade M; Izopet J Diagn Microbiol Infect Dis; 2017 Jan; 87(1):25-27. PubMed ID: 28336133 [TBL] [Abstract][Full Text] [Related]
17. Special commentary: patient safety and the next generation of HPV DNA tests. Kinney W; Stoler MH; Castle PE Am J Clin Pathol; 2010 Aug; 134(2):193-9. PubMed ID: 20660320 [TBL] [Abstract][Full Text] [Related]
18. Testing for human papillomavirus in cervical cancer screening: a review of indications and methodology. Nishino HT; Tambouret RH; Wilbur DC Cancer Cytopathol; 2011 Aug; 119(4):219-27. PubMed ID: 21717588 [TBL] [Abstract][Full Text] [Related]
19. Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer. Arbyn M; Ronco G; Anttila A; Meijer CJ; Poljak M; Ogilvie G; Koliopoulos G; Naucler P; Sankaranarayanan R; Peto J Vaccine; 2012 Nov; 30 Suppl 5():F88-99. PubMed ID: 23199969 [TBL] [Abstract][Full Text] [Related]
20. Diagnostic methods and techniques in cervical cancer prevention Part II: Molecular diagnostics of HPV infection. Vince A; Lepej SZ Med Glas (Zenica); 2010 Feb; 7(1):18-25. PubMed ID: 20387720 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]